2023
DOI: 10.1001/jama.2023.9956
|View full text |Cite
|
Sign up to set email alerts
|

Review of Prediabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 5 publications
0
3
0
Order By: Relevance
“…5 Metformin has numerous randomized control trials supporting its use to prevent and delay type 2 diabetes and is used worldwide to treat prediabetes. 4,6 Despite this, the US Food and Drug Administration has not approved metformin or any other pharmacologic agent to treat prediabetes. 4 Thus, prescribing metformin for prediabetes is technically considered off-label.…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…5 Metformin has numerous randomized control trials supporting its use to prevent and delay type 2 diabetes and is used worldwide to treat prediabetes. 4,6 Despite this, the US Food and Drug Administration has not approved metformin or any other pharmacologic agent to treat prediabetes. 4 Thus, prescribing metformin for prediabetes is technically considered off-label.…”
mentioning
confidence: 99%
“…4,6 Despite this, the US Food and Drug Administration has not approved metformin or any other pharmacologic agent to treat prediabetes. 4 Thus, prescribing metformin for prediabetes is technically considered off-label. However, the American Diabetes Association (ADA) denotes metformin therapy as a consideration for individuals with prediabetes, especially those with BMI ≥35 kg/m 2 , those age <60 years, and women with a history of gestational diabetes (Table 2).…”
mentioning
confidence: 99%
See 1 more Smart Citation